Navigation Links
Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
Date:6/27/2011

ot yet developed metastatic disease.

In the '147 trial, adverse events and serious adverse events were relatively similar between the XGEVA and placebo arms. Hypocalcemia and osteonecrosis of the jaw (ONJ) were reported with increased frequencies in the XGEVA treated patients. The yearly rate of ONJ in the XGEVA arm was similar to prior XGEVA trial results. Back pain was the most common adverse event reported in the XGEVA arm of the trial.

About XGEVA

XGEVA is the first and only RANK Ligand inhibitor approved by the FDA indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. XGEVA was approved following a six month priority review by the FDA.  XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma. XGEVA is the first novel bone metastases treatment for advanced cancer patients in nearly a decade. Delivered as an every four week 120 mg subcutaneous injection, XGEVA provides a unique option for urologists and oncologists to prevent SREs in patients with advanced cancer.

XGEVA is a fully human monoclonal antibody that binds to RANK Ligand, a protein essential for the formation, function and survival of osteoclasts (the cells that break down bone). XGEVA prevents RANK Ligand from activating its receptor, RANK, on the surface of osteoclasts, thereby decreasing bone destruction.

XGEVA has been studied in over 7,000 patients with cancer. In clinical trials, XGEVA demonstrated a clinically meaningful improvement compared to the previous standard of care in preventing bone complications. XGEVA is also being investigated for the potential use to delay the onset of bone metastasis in adjuvant breast cancer.

XGEVA Skeletal-Related Events Regulatory Status

XGEVA is currently approved in the U.S. for the prevention of SREs in patients with bone metastases from solid tumors.  XGEVA was approved following a
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... MA (PRWEB) January 22, 2015 zFlo ... is pleased to announce an exciting product from a new ... motion analysis solutions over the past 15 years, with offerings ... Most recently, their 3D IMU system (inertial measurement unit), iSen, ...
(Date:1/22/2015)... Wilmington, DE (PRWEB) January 22, 2015 ... the Pistoia Alliance, which helps companies check the legal ... set to expand to China. , As their ... companies are globally adopting software solutions built as a ...
(Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... class of therapeutics, known as recombinant attenuated Salmonella ... against fatal diseases including hepatitis B, tuberculosis, cholera, typhoid ... his colleagues at the Biodesign Institute at Arizona State ... safer and more effective. The group, under the direction ...
... five years, Martin Harmer, director of Lehigh,s Center ... team of scientists from Lehigh, Carnegie-Mellon, Clemson, Illinois ... structure of grain-boundary interphasesinterphase complexionsaffect the mechanical, electrical ... strategic engineering materials. The project received $7.5 ...
... examines the science and applications of invisibility, Martin McCall and ... of invisibility cloak that does not just hide objects ... example, McCall and Kinsler explain how a thief could, in ... safe, without even the CCTV surveillance cameras being aware. ...
Cached Biology Technology:New salmonella-based 'clean vaccines' aid the fight against infectious disease 2New salmonella-based 'clean vaccines' aid the fight against infectious disease 3Lehigh University leads Department of Defense MURI grant for atomic-scale interphase research 2Why 'event cloaks' could be the key to the ultimate bank heist 2
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics company, today ... in genetic ancestry of individuals from across the ... more than four hundred years ago, the United ... peoples from different continents. This study illuminates how American history ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... University of Illinois at Urbana-Champaign has received a fiveyear, $5.7 ... in corn. These strains have the potential to combat the ... yield. A team at the Institute for Genomic Biology in ... lead the research. "Ozone can cause major damage ...
... first bulb, heat has been a mostly undesirable byproduct of ... heat at the point of need, on the nanoscale, to ... created by the Rice labs of Michael Wong, Ramon Gonzalez ... Society journal ACS Nano makes use of materials ...
... evades detection and establishes a stronghold without setting off ... this week help explain how the stealthy agent of Black ... The authors of the study, appearing in the Dec. ... Dr. Christopher N. LaRock of the University of Washington Department ...
Cached Biology News:University of Illinois receives grant to study ozone resistance in corn 2Rice uses light to remotely trigger biochemical reactions 2Rice uses light to remotely trigger biochemical reactions 3Rice uses light to remotely trigger biochemical reactions 4Dark Ages scourge enlightens modern struggle between man and microbes 2Dark Ages scourge enlightens modern struggle between man and microbes 3
... Clone/PAD: ZMD.467. Immunogen: Synthetic ... of the human rat mouse dog ... Specific for the human occludin protein. ... cell lysates). Reactivity with rat ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
Biology Products: